Today, ALK and Novozymes have signed an agreement regarding industrially produced allergens, also called recombinant allergens, for use in ALK's future allergy immunotherapy tablets. Under the agreement, Novozymes will initially develop processes for recombinant production of cat allergen on an industrial scale. An estimated 50 million people in Europe and the USA suffer from cat allergy, which makes it the second most common indoor allergy, after house dust mite allergy. ALK retains exclusive product rights and will carry out clinical development, registration and subsequent marketing and sales of the future allergy immunotherapy tablets. Novozymes will provide know-how and manage the production of recombinant allergens. ALK's allergy vaccines treat the actual cause of allergy by exposing the patient's immune system to controlled doses of the same protein substances that trigger the allergic reaction. These proteins are called allergens, and at present they are produced in a complicated process based on natural raw materials. Conversely, recombinant allergens are produced by the use of genetically engineered microbes. One of the advantages of recombinant production is the possibility of easy up-scaling which makes the production of allergy vaccines less dependent on the supply of natural raw materials. The agreement does not change ALK's financial outlook for 2009. ALK-Abelló A/S Jens Bager President and CEO For further information please contact: Jens Bager, President and CEO, tel. +45 4574 7576 Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525 Press: Jacob Frische, tel +45 4574 7551, mobile +45 2224 7551